Malignant adenomyoepithelioma of the breast: clinicopathological features, treatment patterns, and prognostic implications in 97 cases

Malignant adenomyoepithelioma (M-AME) of the breast is an extremely rare biphasic tumor with uncertain biological behavior and limited evidence to guide management. This study aimed to comprehensively analyze the clinical, pathological, and survival features of M-AME. We systematically reviewed the published literature on breast M-AME from 2000 to 2026 and identified 48 eligible studies comprising 86 patients. To enhance the depth of analysis, 11 cases from our institution were included. Data on demographics, tumor characteristics, immunophenotype, molecular alterations, treatment, and clinical outcomes were extracted and analyzed. The majority of patients were female (96 females, 1 male), with a median age of 58 years. Most tumors were triple-negative, estrogen receptor (ER) negative in 76.8%, progesterone receptor (PR) negative in 86.2%, and HER-2 negative in 98.2%. The markers P63, CK7 and CK5/6 were positive in 100%, 94.4%, and 97.0% of cases, respectively. Molecular analysis revealed HRAS mutations in 4 cases and PIK3CA mutations in 3 cases. Surgical management included breast-conserving surgery in 48.7% and mastectomy in 51.3%. Axillary lymph node metastasis was rare. During a median follow-up of 35 months, local recurrence occurred in 5.8% of patients, distant metastasis in 16.3%, and death in 5.8%. M-AME is a rare malignancy characterized by triple-negative immunophenotype, low lymph node metastasis, and significant risks of local recurrence and hematogenous metastasis. Surgical resection remains the cornerstone of management. Individualized adjuvant therapy should be considered based on high risk pathological features. The identification of HRAS and PIK3CA mutations provides potential therapeutic targets. Further large-scale collaborative studies are required to establish evidence-based treatment and prognostic models.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-20
DOI
https://doi.org/10.1186/s13058-026-02408-3
Primary Topic
Breast Lesions and Carcinomas
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Malignant adenomyoepithelioma of the breast: clinicopathological features, treatment patterns, and prognostic implications in 97 cases

Jing Wang, Keyao Xian, Ye Lu, Zhongzhao Wang et al.
1 links
Breast Cancer Research
Breast Lesions and Carcinomas
article

Malignant adenomyoepithelioma of the breast: clinicopathological features, treatment patterns, and prognostic implications in 97 cases

Jing Wang, Keyao Xian, Ye Lu, Zhongzhao Wang, Xiangyi Kong, Wenxiang Zhang, Zheng Li, Xiangyu Wang
article en

Abstract

Malignant adenomyoepithelioma (M-AME) of the breast is an extremely rare biphasic tumor with uncertain biological behavior and limited evidence to guide management. This study aimed to comprehensively analyze the clinical, pathological, and survival features of M-AME. We systematically reviewed the published literature on breast M-AME from 2000 to 2026 and identified 48 eligible studies comprising 86 patients. To enhance the depth of analysis, 11 cases from our institution were included. Data on demographics, tumor characteristics, immunophenotype, molecular alterations, treatment, and clinical outcomes were extracted and analyzed. The majority of patients were female (96 females, 1 male), with a median age of 58 years. Most tumors were triple-negative, estrogen receptor (ER) negative in 76.8%, progesterone receptor (PR) negative in 86.2%, and HER-2 negative in 98.2%. The markers P63, CK7 and CK5/6 were positive in 100%, 94.4%, and 97.0% of cases, respectively. Molecular analysis revealed HRAS mutations in 4 cases and PIK3CA mutations in 3 cases. Surgical management included breast-conserving surgery in 48.7% and mastectomy in 51.3%. Axillary lymph node metastasis was rare. During a median follow-up of 35 months, local recurrence occurred in 5.8% of patients, distant metastasis in 16.3%, and death in 5.8%. M-AME is a rare malignancy characterized by triple-negative immunophenotype, low lymph node metastasis, and significant risks of local recurrence and hematogenous metastasis. Surgical resection remains the cornerstone of management. Individualized adjuvant therapy should be considered based on high risk pathological features. The identification of HRAS and PIK3CA mutations provides potential therapeutic targets. Further large-scale collaborative studies are required to establish evidence-based treatment and prognostic models.

Breast Cancer Research
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN)
National Natural Science Foundation of China
Good health and well-being
Breast Lesions and Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon